A Prospective, Randomized, Double-Blinded, Placebo-Controlled, Multinational, Multicenter, Parallel-group, Phase III Study to Evaluate the Efficacy and Safety of Apatinib Plus Best Supportive Care (BSC) Compared to Placebo Plus BSC in Patients With Advanced or Metastatic Gastric Cancer

Trial Profile

A Prospective, Randomized, Double-Blinded, Placebo-Controlled, Multinational, Multicenter, Parallel-group, Phase III Study to Evaluate the Efficacy and Safety of Apatinib Plus Best Supportive Care (BSC) Compared to Placebo Plus BSC in Patients With Advanced or Metastatic Gastric Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Apr 2018

At a glance

  • Drugs Rivoceranib (Primary)
  • Indications Gastric cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ANGEL
  • Sponsors LSK Biopharma
  • Most Recent Events

    • 20 Dec 2017 According to a LSK Biopharma media release, 1/3 of total expected patients have been enrolled in this trial. This was designed with input from the US FDA, the PMDA (Japan), EMA (EU), TFDA (Taiwan), and MFDS (South Korea).
    • 20 Dec 2017 According to a LSK Biopharma media release, the first US and European patients have been enrolled in this trial.
    • 06 Jun 2017 Trial design presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top